Alpha Cognition is trading 5.41% lower at $8.30, with the decline appearing primarily driven by broad biotech weakness. - XBI is down 2.04% as higher Treasury yields, inflation concerns and broad market weakness pressure growth-oriented biotech stocks. - No new company-specific announcement was identified for September 24, 2026; the latest release was a September 9 inducement-grant filing, not a fresh negative catalyst. - Confidence is medium; direct company-specific causation was not reported.